Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
Health Science Reports|July 5, 2023
Clinical characteristics of COVID-19 patients infected by the Omicron variants in Macao, China: A cross-sectional studyHou Hon Cheong, Fong I Sio, Chi Chung Chan, et al.Bioorganic & Medicinal Chemistry Letters|October 24, 2002
Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profileYves Leblanc, Patrick Roy, Zhaoyin Wang, et al.Bioorganic & Medicinal Chemistry Letters|November 4, 2011
Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacyDavid A Powell, W Cameron Black, Kelly Bleasby, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
HIP1-ALK, a novel ALK fusion variant that responds to crizotinibDouglas D Fang, Bin Zhang, Qingyang Gu, et al.Archives of Internal Medicine|December 14, 2005
Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemiaChor-Sang Chim, Yok-Lam Kwong, Albert Kwok-Wei Lie, et al.Bioorganic & Medicinal Chemistry Letters|April 26, 2024
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitorZhaobing Xu, Yingchun Liu, Baohui Song, et al.Bioorganic & Medicinal Chemistry Letters|August 26, 2006
Comparison between two classes of selective EP(3) antagonists and their biological activitiesMichel Belley, Chi Chung Chan, Yves Gareau, et al.Oncotarget|June 12, 2015
Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical developmentQingyang Gu, Bin Zhang, Hongye Sun, et al.Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonistsMichel Belley, Michel Gallant, Bruno Roy, et al.Bioorganic & Medicinal Chemistry Letters|April 22, 2011
Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonistsDaniel Guay, Christian Beaulieu, Michel Belley, et al.Pageof 5